FDA Approval of Synergy Disc® Marks Advancement in Motion-Preserving Spine Surgery

The recent FDA approval of the Synergy Disc® for single-level cervical disc replacement represents a meaningful step forward in motion-preserving spine care. As a principal investigator in the U.S. IDE trial, Dr. Todd H. Lanman played a key role in the clinical research supporting this approval and will present outcomes at ISASS 2026 in Miami.

Designed to preserve motion while improving spinal alignment, the Synergy Disc introduces a new category of cervical disc technology with strong clinical results compared to fusion. This milestone reflects continued progress in expanding treatment options for appropriately selected patients and advancing the standard of care in disc arthroplasty.